Mark Lingen to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Mark Lingen has written about Dose-Response Relationship, Drug.
Connection Strength
0.040
-
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
Score: 0.028
-
Recombinant human uteroglobin/CC10 inhibits the adhesion and migration of primary human endothelial cells via specific and saturable binding to fibronectin. J Cell Physiol. 2006 May; 207(2):553-61.
Score: 0.012